Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Endocrinology
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Related Questions
How do you treat metastatic large cell neuroendocrine carcinoma of prostate with undetectable PSA, who had the treatment related transformation while on ADT monotherapy?
Why are patients getting enzalutamide s/p prostatectomy not candidates for salvage radiation therapy?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
How would you treat a patient presenting with de novo metastatic prostate cancer and baseline low testosterone?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
In what situations would a standard FDG PET/CT be useful in the evaluation of high risk prostate cancer?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
Under what circumstances would you treat prostate cancer without a biopsy?
Does a negative staging PSMA PET in a patient with biopsy-proven recurrent prostatic adenocarcinoma change your management?
